AirSculpt Technologies, Inc. (AIRS) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. AirSculpt Technologies, Inc. is a national provider of body contouring procedures using its proprietary AirSculpt® method. As of May 8, 2026, the company operated 31 centers across 20 states and Canada. The company is classified as an emerging growth company and a smaller reporting company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $39.4 million | $39.4 million |
| Net Loss | $(2.4) million | $(2.8) million |
| Adjusted EBITDA | $3.3 million | $3.8 million |
| Operating Cash Flow | $5.3 million | $0.9 million |
| Cash and Equivalents | $16.7 million | $5.6 million |
| Total Debt (Net) | $44.8 million | $56.0 million |
| Loss Per Share (Diluted) | $(0.03) | $(0.05) |
Material Changes vs. Prior Period
- Revenue Stability: Revenue remained essentially flat year-over-year ($39.4M), driven by a 0.2% increase in case volume (3,082 cases) offset by a slight decrease in revenue per case ($12,780 vs. $12,799).
- Cost Management: Cost of service decreased 2.3% to $15.6M, primarily due to a $0.4M reduction in medical payroll. Selling, General, and Administrative (SG&A) expenses increased 3.7% to $22.6M, driven by higher professional service fees and advertising, partially offset by lower stock compensation.
- Debt Reduction: The company voluntarily prepaid $10.0 million of its term loan principal during the quarter, reducing total debt from $56.0M to $44.8M. This action terminated a $10.0 million limited guarantee previously provided by the company's private equity sponsor.
- Liquidity Improvement: Cash and cash equivalents more than doubled to $16.7M, supported by $14.6M in net proceeds from an At-The-Market (ATM) equity offering and strong operating cash flow.
Outlook, Risks, and Unusual Items
- Capital Strategy: The company utilized proceeds from the ATM offering to reduce debt. It maintains a $5.0 million revolving credit facility with full availability.
- Internal Control Weaknesses: Management concluded that disclosure controls and procedures were not effective as of March 31, 2026. Material weaknesses persist in general accounting processes and lease accounting (ASC 842), requiring revision of previously issued financial statements. Remediation is ongoing but not yet complete.
- Forward-Looking Risks: Key risks include competition from weight-loss drugs, inability to stabilize same-center performance, rising inflation, and potential litigation or medical malpractice claims. The company notes that future results could differ materially from projections.
- Unusual Items: The quarter included $0.6M in one-time SOX compliance costs and $0.95M in restructuring/severance costs, which were excluded from Adjusted EBITDA.
Investor Verification Checklist
- Verify the status of remediation for the material weaknesses in internal controls over financial reporting, specifically regarding lease accounting and general accounting processes.
- Monitor the impact of weight-loss drug market acceptance on case volumes and revenue per case in upcoming quarters.
- Review the company's ability to maintain the minimum liquidity covenants ($7.5M) required by its Credit Agreement.
- Assess the sustainability of operating cash flow given the flat revenue growth and continued net losses.
- Confirm the details of the debt covenant compliance, particularly the Consolidated Leverage Ratio and Fixed Charge Coverage Ratio.